SARS-CoV-2 seropositivity in renal transplant patients administered intravenous immunoglobulin

Transpl Infect Dis. 2023 Jun;25(3):e14016. doi: 10.1111/tid.14016. Epub 2023 Feb 15.

Authors

Beatrice Z Sim^{1

2}, Bernice L Sim³, Matthew J Tunbridge^{1

4}, Griffith Boord Perkins⁴, Cheng Sheng Chai⁴, Patrick Toby Coates^{1

4}

Affiliations

¹ Central and Northern Adelaide Renal and Transplantation Services, Adelaide, South Australia, Australia.
² National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
³ St George's University of London, London, UK.
⁴ University of Adelaide, Adelaide, South Australia, UK.

PMID: 36748730
DOI: 10.1111/tid.14016

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Viral
COVID-19*
Humans
Immunoglobulins, Intravenous / therapeutic use
Kidney Transplantation* / adverse effects
SARS-CoV-2

Substances

Immunoglobulins, Intravenous
Antibodies, Viral

Grants and funding

Hospital Research Foundation Group